Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point of care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

For more information, click below.


Subscribers log in here


Transfusion-associated graft-versus-host disease

INTRODUCTION

Graft-versus-host disease (GVHD) is a rare, almost always fatal complication of a blood transfusion. It occurs much more commonly after hematopoietic cell transplant (HCT), a setting in which it is less severe — mortality rate of 20 to 25 percent following transplantation versus 80 to 90 percent when associated with a transfusion [1,2].

GVHD results from an attack by viable immunocompetent donor lymphocytes on the recipient's antigen presenting tissues. This immunologic assault is manifested clinically by dysfunction of the skin, liver, gastrointestinal tract and bone marrow. The effect on the bone marrow distinguishes transfusion-associated GVHD (ta-GVHD) from transplantation-associated disease. With HCT, the bone marrow cells in the recipient are of donor origin and are therefore exempted from attack. Thus, bone marrow aplasia, which is the primary cause of death in ta-GVHD, is an infrequent complication after HCT [3].

PATHOGENESIS AND INCIDENCE

GVHD does not occur after most transfusions because the donor lymphocytes are destroyed by the recipient's immune system before they can mount a response against the host. However, this protective response does not occur in two settings: when the recipient is immunodeficient; and when there is a specific type of partial HLA matching between the donor and recipient.

Immunodeficient states — Transfusion-associated GVHD was first described in 1965 in a cohort of immunodeficient children [4]. Over the next 15 years, 38 cases were reported in a number of different immunodeficient states, including newborns with erythroblastosis fetalis, Hodgkin's and non-Hodgkin lymphoma, and acute and chronic leukemia [5]. Other patients at risk include those with solid tumors who are immunosuppressed because of chemotherapy (eg, purine analog therapy) or radiation and severe congenital or acquired immune deficiency [6-8].

By 1980, the incidence of ta-GVHD was estimated at 0.1 to 1.0 percent in patients with hematologic cancers or lymphoproliferative disorders. With the increased use of irradiation and leukoreduction of blood products in the 1990s, as well as a decreased use of fresh blood and directed donations, the incidence of ta-GVHD has fallen considerably. As an example, the incidence of ta-GVHD was approximately 0.15 percent in Japan between 1981 and 1986, whereas there were no cases reported in Japan during 2000 or 2001 [6].

               

Subscribers log in here

To continue reading this article you must have access through your hospital or your group practice, log in to your personal subscription, or purchase a personal subscription. For more information, click below.
Literature review current through: May 2013. | This topic last updated: Sep 14, 2012.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2013 UpToDate, Inc.
References
Top
  1. Linden JV, Pisciotto PT. Transfusion-associated graft-versus-host disease and blood irradiation. Transfus Med Rev 1992; 6:116.
  2. Fast LD. Developments in the prevention of transfusion-associated graft-versus-host disease. Br J Haematol 2012; 158:563.
  3. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324:667.
  4. Hathaway WE, Githens JH, Blackburn WR, et al. Aplastic anemia, histiocytosis and erythrodermia in immunologically deficient children. Probable human runt disease. N Engl J Med 1965; 273:953.
  5. Brubaker DB. Human posttransfusion graft-versus-host disease. Vox Sang 1983; 45:401.
  6. Schroeder ML. Transfusion-associated graft-versus-host disease. Br J Haematol 2002; 117:275.
  7. Maung ZT, Wood AC, Jackson GH, et al. Transfusion-associated graft-versus-host disease in fludarabine-treated B-chronic lymphocytic leukaemia. Br J Haematol 1994; 88:649.
  8. Leitman SF, Tisdale JF, Bolan CD, et al. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus. Transfusion 2003; 43:1667.
  9. Sakakibara T, Juji T. Post-transfusion graft-versus-host disease after open heart surgery. Lancet 1986; 2:1099.
  10. Shivdasani RA, Haluska FG, Dock NL, et al. Brief report: graft-versus-host disease associated with transfusion of blood from unrelated HLA-homozygous donors. N Engl J Med 1993; 328:766.
  11. Aoun E, Shamseddine A, Chehal A, et al. Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center. Transfusion 2003; 43:1672.
  12. FDA Memorandum: License amendments and procedures for gamma irradiation of blood products. June 22, 1993.
  13. von Fliedner V, Higby DJ, Kim U. Graft-versus-host reaction following blood product transfusion. Am J Med 1982; 72:951.
  14. Leitman SF, Holland PV. Irradiation of blood products. Indications and guidelines. Transfusion 1985; 25:293.
  15. De Dobbeleer GD, Ledoux-Corbusier MH, Achten GA. Graft versus host reaction. An ultrastructural study. Arch Dermatol 1975; 111:1597.
  16. Woods WG, Lubin BH. Fatal graft versus host disease following a blood transfusion in a child with neuroblastoma. Pediatrics 1981; 67:217.
  17. Rosen RC, Huestis DW, Corrigan JJ Jr. Acute leukemia and granulocyte transfusion: Fatal graft-versus-host reaction following transfusion of cells obtained from normal donors. J Pediatr 1978; 93:268.
  18. Betzhold J, Hong R. Fatal graft-versus-host disease after a small leukocyte transfusion in a patient with lymphoma and varicella. Pediatrics 1978; 62:63.
  19. Hutchinson K, Kopko PM, Muto KN, et al. Early diagnosis and successful treatment of a patient with transfusion-associated GVHD with autologous peripheral blood progenitor cell transplantation. Transfusion 2002; 42:1567.
  20. Neves JF, Marques A, Valente R, Barata D. Nonlethal, attenuated, transfusion-associated graft-versus-host disease in an immunocompromised child: case report and review of the literature. Transfusion 2010; 50:2484.
  21. Agbaht K, Altintas ND, Topeli A, et al. Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature. Transfusion 2007; 47:1405.
  22. Triulzi D, Duquesnoy R, Nichols L, et al. Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion 2006; 46:885.
  23. Klein HG. Transfusion-associated graft-versus-host disease: less fresh blood and more gray (Gy) for an aging population. Transfusion 2006; 46:878.
  24. Williamson LM, Stainsby D, Jones H, et al. The impact of universal leukodepletion of the blood supply on hemovigilance reports of posttransfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007; 47:1455.
  25. Akahoshi M, Takanashi M, Masuda M, et al. A case of transfusion-associated graft-versus-host disease not prevented by white cell-reduction filters. Transfusion 1992; 32:169.
  26. Hayashi H, Nishiuchi T, Tamura H, Takeda K. Transfusion-associated graft-versus-host disease caused by leukocyte-filtered stored blood. Anesthesiology 1993; 79:1419.
  27. Fast LD, DiLeone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51:1397.
  28. Grass JA, Wafa T, Reames A, et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93:3140.